LYs and $271.3 billion (B) due to cervical cancer alone over the next 20 years. Based on a realistic linear investment model, RT yields an additional 9.8M LYs (2.9M in LIC, 4.7M in LMIC, and 2.2M in UMIC) over 20 years, a $53.2B net increase in economic productivity ($2.6B in LIC, $16.4B in LMIC, and $34.2B in UMIC), and a broader societal net gain of $137.5B ($10.3B in LIC, $44.8B in LMIC, and $82.4B in UMIC). The additional investment necessary for HDR brachytherapy, an essential component of curative treatment, was only 5.5% greater than EBRT alone. **Conclusions:** The failure to ensure global availability of EBRT and BT to treat cervical cancer would result in enormous human and economic consequences over the next two decades. This loss would occur before the benefits of primary cancer prevention strategies, such as HPV vaccination, are realized. The present study demonstrates that a realistic investment strategy over the next 20 years may yield a net economic benefit of up to $150B USD, and potentially further benefits beyond that point in time. These findings support the value of scaling-up of EBRT and BT to treat cervical cancer and help to justify their inclusion in national cancer control planning.

12

UTILIZATION OF EMERGENCY DEPARTMENTS AMONG PATIENTS WITH CANCER

Harvey Quon[1], Mark Smith[2], Lisa Lix[2], Jane Griffith[1], Heather Prior[2], Say Hong[2], Ankona Banerjee[2], Ina Koseva[2], Christina Kulbaba[2]
[1]CancerCare Manitoba, Winnipeg, MB
[2]Manitoba Centre for Health Policy, Winnipeg, MB

Purpose: To compare emergency department (ED) use between patients with cancer and a matched cancer-free cohort of individuals and to examine the association between ED use and time to death.
Methods and Materials: Data were from the Manitoba Centre for Health Policy Data Repository and included cancer registry, hospital discharge abstracts, physician billing claims, ED visits, and vital statistics. The cancer cohort included adults (age 18+) with selected cancer diagnoses (breast, colorectal, lung and prostate) made between 2007 and 2011. Rates of ED utilization were compared during three time periods (pre-, peri-, and post-diagnosis) using generalized estimating equations between cancer patients and cancer-free individuals matched 1:1 on age, sex, and Charlson comorbidity score. The association between ED use and time to death was tested using a multivariable Cox proportional hazards regression model.
Results: A total of 5569 patients with breast (n = 1555), colorectal (n = 1327), lung (n = 1437), and prostate (n = 1250) cancer were included. When comparing ED utilization between cancer cases by site and their matches only lung cancer showed a significant increase during the pre-diagnosis period (relative rate [RR] 1.38 [95% confidence interval 1.18-1.62], p < 0.0001). ED utilization was increased during the peri-diagnosis period for breast (RR 1.74 [1.31-2.32], p = 0.0001), colorectal (RR 2.44 [1.72-3.45], p < 0.0001), lung (RR 4.51 [3.61-5.63], p < 0.0001), and prostate (RR 3.10 [2.14-4.47], p < 0.0001) cancer. In the post-diagnosis period, ED utilization was increased for breast (RR 1.45 [1.26-1.67], p < 0.0001), colorectal (RR 1.40 [1.11-1.76, p = 0.0005), and lung (RR 2.28 [1.94-2.67], p < 0.0001) cancer. ED use in the year prior to diagnosis was associated with time to death for prostate cancer (hazard ratio [HR] 1.12 [95% CI 1.02-1.24], p < 0.02) while ED use in the post-diagnosis period was associated with time to death for breast (HR 1.27 [1.18-1.37], p < 0.0001), colorectal (HR 1.11 [1.04-1.18], p = 0.0012), and lung (HR 1.10 [1.06-1.14], p < 0.0001) cancer.
Conclusions: The pattern of ED utilization varies with cancer site and time from diagnosis. All cancer sites were associated with increased ED use around the time of diagnosis, while patients with breast, colorectal, and lung cancers also showed increased ED use in the post-diagnosis period. Additional cancer-related urgent care services during the peri- and post-diagnosis periods may alleviate the frequency of ED visits among patients with cancer.

13

POST-OPERATIVE "MINIPELVIS" RADIOTHERAPY WITH OR WITHOUT VAGINAL VAULT BRACHYTHERAPY BOOST FOR STAGE II ENDOMETRIAL CANCER

Kim Paulson, Natalie Logie, Fleur Huang, Robert Pearcey, Sunita Ghosh, Brad Murray, Geetha Menon, Ericka Wiebe
University of Alberta, Edmonton, AB

Purpose: Patients with FIGO Stage II endometrial cancer (EC) are generally treated surgically, with risk-adapted adjuvant radiotherapy (external beam radiotherapy (EBRT) and/or vaginal vault brachytherapy (BT) boost) still suboptimally defined. With changing surgical practices in nodal assessment and/or resection, opportunity exists for selected patients to receive less intensive adjuvant therapy, with the goal of lessening treatment-related morbidity. In this single-institutional review, we explore outcomes of Stage II EC patients treated with adjuvant "minipelvis" (MP)-EBRT (a field covering at least the surgical bed, vaginal vault, and parametria, but not the classical elective nodal regions) +/- BT.
Methods: Women with pathologic Stage II EC receiving post-operative MP-EBRT from 2000 onwards were reviewed. Demographics, disease characteristics, treatment details, survival, and recurrence data were collected. Three-year relapse-free survival (RFS) and overall survival (OS) were calculated from the date of surgery (Kaplan-Meier method). Median RFS and OS were compared between those receiving MP-EBRT+BT and those receiving MP-EBRT alone (log rank test). Univariate analysis was performed (binary logistic regression) to determine factors associated with relapse.
Results: n = 42 patients (median age 63 years [36-86]) received adjuvant MP-EBRT (2000-2015), with median follow up 27 months (2-105). n = 37 (88%) had pelvic lymph node dissection. Endometrioid adenocarcinoma was predominant (71%) over other histologies. n = 20 had Grade 3 disease, n = 18 had deep (> 50%) myometrial invasion (MI), and n = 22 had lymphovascular invasion (LVI). n = 10 received adjuvant chemotherapy. MP-EBRT fields had conventional inferior and lateral borders and height less than 12 cm (range 7.8-11.8). Dose fractionation was typically 45 Gy in 25 fractions (40-52.6 Gy/20-25), and 32 (76%) received subsequent HDR BT boost, typically 15 Gy in three fractions (15-18 Gy/3) prescribed to vaginal surface. Ten patients relapsed (one vaginal recurrence, three in pelvis outside the field, six distant), four (40%) of those not receiving BT versus 19% of the BT group (OR 3.5, 95%CI 0.7-16.9, p = 0.125). Median time to relapse was 20 months (10-32). Tumour grade, LVI, and MI were not significantly associated with relapse. Three-year RFS and OS were 74% and 92% respectively.
Conclusions: In this small series, early outcomes following adjuvant MP-EBRT for Stage II EC align with those reported for conventional adjuvant EBRT, suggesting that this is a reasonable approach. Only three patients relapsed in the pelvis outside of the field. Further characterization of tumour and toxicity outcomes can help to better define the population most likely to benefit from MP-EBRT, and the value of BT boost in this setting.

14

CURRENT PRACTICE OF BRACHYTHERAPY AND EXTERNAL BEAM RADIOTHERAPY FOR CERVICAL CANCER IN ONTARIO, CANADA

Negin Shahid[1], Timothy Craig[1], Mary Westerland[2], Allison Ashworth[2], Michelle Ang[3], David D'Souza[4], Raxa Sankreacha[5], Anthony Fyles[1], Michael Milosevic[1], Iwa Kong[6]
[1]University of Toronto, Toronto, ON
[2]Cancer Centre of Southeastern Ontario, Kingston, ON
[3]Cancer Care Ontario, Toronto, ON
[4]University of Western Ontario, London, ON
[5]Trillium Health Partners, Mississauga, ON
[6]McMaster University, Hamilton, ON

Purpose: To document the practice of brachytherapy (BT) and external beam radiotherapy (EBRT) for management of cervical cancer across Ontario, Canada with a population of 13.6 million.
Methods and Materials: An electronic survey (SurveyMonkey)